Key Insights

Highlights

Success Rate

86% trial completion

Published Results

28 trials with published results (21%)

Research Maturity

84 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.7%

14 terminated out of 131 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

12%

16 trials in Phase 3/4

Results Transparency

33%

28 of 84 completed with results

Key Signals

28 with results86% success14 terminated

Data Visualizations

Phase Distribution

87Total
Not Applicable (19)
Early P 1 (3)
P 1 (17)
P 2 (32)
P 3 (6)
P 4 (10)

Trial Status

Completed84
Terminated14
Unknown14
Recruiting9
Active Not Recruiting6
Not Yet Recruiting2

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 84 completed trials

Clinical Trials (131)

Showing 20 of 20 trials
NCT05736419Phase 2Recruiting

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT03692052Phase 2Active Not RecruitingPrimary

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

NCT04208529Phase 3Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT06609226Phase 3Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT05477563Phase 3Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT02386800Phase 4Active Not Recruiting

CINC424A2X01B Rollover Protocol

NCT01758042Not ApplicableCompleted

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT03249831Phase 1Active Not Recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT05356195Phase 3Active Not Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT05508932Recruiting

Atrial Fibrillation in Beta-Thalassemia

NCT06313398Early Phase 1Recruiting

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

NCT01911871CompletedPrimary

Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations

NCT07352878Not Yet RecruitingPrimary

Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.

NCT04398628Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT07023029Phase 1Completed

A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

NCT06581627Phase 1Completed

A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

NCT03655678Phase 2Completed

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT04987489Phase 2Completed

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT07210450Phase 2Completed

Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia

NCT07099196Not ApplicableCompleted

Impact of Virtual Reality on Pain and Anxiety During Intravenous Cannulation Procedures Among Thalassemia Patients in UAE.

Scroll to load more

Research Network

Activity Timeline